Session » Healthcare Disparities in Rheumatology Poster

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 269

Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials

9:00AM-11:00AM: Abstract Number: 266

Diagnostic Delays and Disparities in Access to Care in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 265

Disparities in Utilization and Direct Costs of Hospitalizations and Emergency Room Visits in SLE: The Georgia Lupus Registry

9:00AM-11:00AM: Abstract Number: 272

Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry

9:00AM-11:00AM: Abstract Number: 270

Gaps in Knowledge about the Ontario Trillium Drug Program

9:00AM-11:00AM: Abstract Number: 276

Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 271

Health Care Disparities for Infectious and Non-Infectious Uveitis in the US

9:00AM-11:00AM: Abstract Number: 275

Health Equity: Access to Rituximab for Patients Comparing Variable Access in a Single Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 273

Incidence of Systemic Lupus Erythematosus By Income: A Nationwide Study

9:00AM-11:00AM: Abstract Number: 277

Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population

9:00AM-11:00AM: Abstract Number: 267

Patterns of Access to Prescription Medications Among Lupus Cases and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

9:00AM-11:00AM: Abstract Number: 263

Racial Disparities in Total Knee Replacement Failure Are Not Explained By Poverty

9:00AM-11:00AM: Abstract Number: 264

Relationships between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 274

Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 278

The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study

9:00AM-11:00AM: Abstract Number: 268

The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)

9:00AM-11:00AM: Abstract Number: 279

Variations and Disparities in Healthcare Teams Among Individuals with Lupus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].